Concord Medical Services (NYSE:CCM) is one of China’s leading providers of radiotherapy equipment and oncology services. The company specializes in supplying and operating advanced radiotherapy machines, including linear accelerators, computed tomography (CT) simulators and brachytherapy units, to public and private hospitals. Through its integrated service model, Concord Medical Services delivers treatment planning, machine maintenance and clinical support to enhance the precision and effectiveness of cancer therapies.
Founded in 1997 and headquartered in Beijing, Concord Medical Services has developed an extensive network of oncology centers across major cities and provinces in China. The company typically partners with top-tier public hospitals to establish dedicated radiotherapy departments, combining its proprietary equipment management system with on-site technical teams. This collaborative approach allows hospital partners to expand access to high-precision treatment modalities, while Concord Medical Services oversees installation, quality assurance and ongoing clinical training for medical staff.
In addition to equipment provision, Concord Medical Services offers comprehensive consulting services that encompass treatment protocol design, dosimetry verification and patient data management. The company’s technology platform integrates imaging, treatment planning and delivery data, enabling clinicians to streamline workflows and monitor outcomes in real time. Concord Medical Services also provides preventive maintenance and rapid-response repair services, ensuring minimal downtime for critical cancer therapy equipment.
Since its initial public offering on the New York Stock Exchange in 2016, Concord Medical Services has continued to expand its footprint by pursuing new hospital partnerships and exploring advanced modalities such as image-guided radiotherapy and proton therapy. With a focus on innovation and quality assurance, the company aims to address the growing demand for precision oncology services across China’s rapidly aging and urbanizing population.
